50% of travelers cannot remember the last advertisement they saw for a tourism company or destination, with a further 7% unsure Tourism faces an $11 billion marketing investment gap: restoring the category’s share of voice to 3% would require global travel and transport ad spend to reach $43.4 billion by 2027 63% of Large Language Model (LLM) visibility is driven by long-term brand equity, compared with 22% from current marketing activity and 11% from citation volume TOURISE, the world’s premier...
Nomios Expands Presence in Southern Europe with Leading Portuguese Cybersecurity Services Specialist Orbcom
illumynt Expands Ohio Operations to Support Growing Demand for Advanced Technology Lifecycle Services
The Empire State Building Observation Deck Hosts Annual Run-Up, Presented by NYU Langone Health and Powered by Merrell
Climate hopes shift from politics to the courts
Climate hopes shift from politics to the courts
Strong international interest in Security Essen and EUDEX / From Albania to Uzbekistan – visitors from almost 90 nations
Physical AI has a system problem. Machines that perceive, reason and act in the real world cannot scale by adding AI accelerators alone. Compute, memory capacity, memory bandwidth, connectivity, and software must scale together and continue scaling as the AI models and application workloads evolve. Today, EdgeCortix®, a leading Japanese fabless semiconductor company specializing in energy-efficient AI processing, unveiled RAIDEN™, its next-generation scalable AI chiplet platform purpose-built to...
HeadFirst Global, a leader in work orchestration, today announced it will become Vertage, as it builds a global technology platform that dynamically curates the right mix of expert talent and AI agents to deliver the work outcomes enterprises need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923823506/en/Edzard Overbeek, Group CEO at Vertage The €10 billion group is bringing its 11 operating businesses together under the Vertage...
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years Tumor responses remained robust 1 and durable 2 Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in sympto...
